---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Cost assumptions"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Cost assumptions. Topics: Ficerafusp alfa dose and schedule in the pivotal trial, Pembrolizumab list price, Pembrolizumab dose and maximum treatment duration, Real-world time on first-line pembrolizumab treatment, and 5 further topics. 9 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics/cost-assumptions"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Cost assumptions

<a id="heading-4.2.4"></a>

## 4.2.4 Cost Assumptions

<a id="topic-4.2.4-1"></a>

### Budget impact model of ficerafusp alfa: cost assumptions

No evidence found.

<a id="topic-4.2.4-2"></a>

### Ficerafusp alfa price

No evidence found.

<a id="topic-4.2.4-3"></a>

### Ficerafusp alfa dose and schedule in the pivotal trial

> “1500mg dosed once weekly, or QW, of ficerafusp alfa in combination with pembrolizumab”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-4.2.4-4"></a>

### Pembrolizumab list price

> “for each indicated dose of KEYTRUDA when given every 3 weeks is $12,517.44.”
> “The list price for each indicated dose of KEYTRUDA when given every 6 weeks is $25,034.88.”
> “The list price is also referred to as wholesale acquisition cost or WAC.”
> “The list price does not include other treatment-related costs. The list price is current as of September 2026.”

Source: [Merck KEYTRUDA cost information (2026)](https://www.keytruda.com/financial-support/)

<a id="topic-4.2.4-5"></a>

### Pembrolizumab dose and maximum treatment duration

> “HNSCC: 200 mg every 3 weeks or 400 mg every 6 weeks.”
> “Treatment with KEYTRUDA continued until RECIST v1.1-defined progression of disease as determined by the investigator, unacceptable toxicity, or a maximum of 24 months.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-4.2.4-6"></a>

### Real-world time on first-line pembrolizumab treatment

> “The median (95% CI) rwToT for the monotherapy group was 4.2 (3.5–4.6) months, while the median (95% CI) rwTTNT was 6.5 (5.4–7.4) months”
> “The median rwToTs observed in the current study were also numerically similar to the corresponding median durations of study therapy observed in KEYNOTE-048 (4.2 versus 3.5 months for pembrolizumab monotherapy and 4.9 versus 5.8 months for pembrolizumab plus chemotherapy)”

Source: [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)

<a id="topic-4.2.4-7"></a>

### Cetuximab list price

> “The list price1 of Erbitux is $17,235.60 per month, but the amount you pay will largely depend on your insurance plan.”
> “The dosing and pricing assumptions for a monthly supply of Erbitux are based on an average-sized patient by indication.”

Source: [Lilly ERBITUX cost information (2026)](https://www.lillypricinginfo.com/erbitux)

<a id="topic-4.2.4-8"></a>

### Cetuximab dose with chemotherapy

> “Weekly: Administer initial dose of 400 mg/m2 as a 120-minute intravenous infusion, and subsequent doses of 250 mg/m2 infused over 60 minutes once weekly.”
> “Biweekly: Administer 500 mg/m2 as a 120-minute intravenous infusion every two weeks.”

Source: [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

<a id="topic-4.2.4-9"></a>

### United States unit drug, administration, and terminal care costs used in a first-line cost-effectiveness model

| Input | Value (95% CI) |
| --- | --- |
| Nivolumab, drug cost per 1 mg, $ | “30 (29–32)” |
| Cisplatin, drug cost per 1 mg, $ | “0.17 (0.14–0.2)” |
| Carboplatin, drug cost per 1 mg, $ | “0.05 (0.04–0.06)” |
| Fluorouracil, drug cost per 1 mg, $ | “0.005 (0.004–0.006)” |
| Cetuximab, drug cost per 1 mg, $ | “7.04 (5.63–8.44)” |
| Terminal care cost per patient, $ | “11,126 (8901–13,351)” |
| Best supportive care cost per cycle, $ | “4645 (3716–5574)” |
| Drug administration, first hour, $ | “150.34 (123.55–198.06)” |
| Drug administration, additional hour, $ | “32.23 (27.29–41.02)” |

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10957979/)

<a id="topic-4.2.4-10"></a>

### Cost categories in a first-line cost-effectiveness model of pembrolizumab regimens

> “Costs included first-line and subsequent treatments, disease management, adverse events, and terminal care costs.”

Source: [Borse et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35765888/)

<a id="topic-4.2.4-11"></a>

### Incremental monthly health care costs associated with recurrence

> “Recurrence was associated with higher HCRU and monthly health care costs in both resected ($3,831; 95% CI = $2,319-$5,360) and unresected ($4,730; 95% CI = $3,611-$5,870) groups (P < 0.001).”

Source: [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

Additional sources: [Haddad et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31928375/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
